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Abstract
Background: Psychotic disorders are a group of severe mental disorders that cause considerable disability to
sufferers and a high level of burden to families. In many low- and middle-income countries (LMIC), traditional and
faith healers are the main providers of care to affected persons. Even though frequently canvassed as desirable for
improved care delivery, collaboration between these complementary alternative health providers (CAPs) and
conventional health providers has yet to be rigorously tested for feasibility and effectiveness on patient outcomes.
Methods/design: COSIMPO is a single-blind, cluster randomized controlled trial (RCT) being conducted in Nigeria
and Ghana to compare the effectiveness of a collaborative shared care (CSC) intervention program implemented by
CAPs and primary health care providers (PHCPs) with care as usual (CAU) at improving the outcome of patients
with psychosis. The study is designed to test the hypotheses that patients receiving CSC will have a better clinical
outcome and experience fewer harmful treatment practices from the CAPs than patients receiving CAU at
6 months after study entry. An estimated sample of 296 participants will be recruited from across 51 clusters, with a
cluster consisting of a primary care clinic and its neighboring CAP facilities. CSC is a manualized intervention
package consisting of regular and scheduled visits of PHCPs to CAP facilities to assist with the management of trial
participants. Assistance includes the administration of antipsychotic medications, management of comorbid
physical condition, assisting the CAP to avoid harmful treatment practices, and engaging with CAPs, caregivers and
participants in planning discharge and rehabilitation. The primary outcome, assessed at 6 months following trial
entry, is improvement on the Positive and Negative Symptom Scale (PANSS). Secondary outcomes, assessed at 3
and 6 months, consist of levels of disability, experience of harmful treatment practices and of victimization, and
levels of perceived stigma and of caregivers’ burden.
Discussion: Information about whether collaboration between orthodox and complementary health providers is
feasible and can lead to improved outcome for patients is important to formulating policies designed to formally
engage the services of traditional and faith healers within the public health system.
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Keywords: Complementary alternative providers, Primary care, Collaboration, psychosis
* Correspondence: ogureje@com.ui.edu.ng
1Department of Psychiatry, University of Ibadan, Ibadan, Nigeria
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gureje et al. Trials  (2017) 18:462 
DOI 10.1186/s13063-017-2187-x
Background
Psychotic disorders are a group of severe mental disorders
that cause considerable disability to sufferers and signifi-
cant burden to families and caregivers. The Global Burden
of Disease project estimates that, in 2010, schizophrenia
was responsible for 1.1% of all Disability-adjusted Life
Years due to non-communicable diseases and 2.4% of
Years Lived with Disability [1, 2]. Even though relatively
low-cost and effective treatments are available for psych-
otic disorders [3–5], only very few persons affected by
these disorders receive any treatment in low- and middle-
income countries (LMIC). Community studies in sub-
Saharan Africa show that only about 20% of persons with
severe mental disorders had received any treatment in the
prior 12 months [6, 7]. A study conducted in Nigeria
found that symptoms of non-affective psychoses were
relatively common, with a prevalence of 1.1%. The major-
ity of those who reported the conditions had not received
any treatment [7].
It has been estimated that 80% of the world’s rural
poor rely on complementary alternative health providers
(CAPs) for their health care [8]. There is evidence from
LMIC to indicate that CAPs, principally consisting of
traditional healers (TH) and faith healers (FH)), consti-
tute a large proportion of the de facto human mental
health resource for health care service [9, 10]. Commu-
nity surveys in these countries show that traditional
health practitioners (THP) are often the first health care
providers contacted by persons with a variety of mental
health conditions [11]. There is also evidence that some
patients continue with simultaneous consultations to
CAPs and conventional health providers [11–13]. Stud-
ies conducted in Uganda show that about 60% of pa-
tients consulting THPs have diagnosable Diagnostic and
Statistic Manual of Mental Disorders, version IV (DSM-
IV) disorders, with about 30% of these being cases of
psychosis [14, 15]. In LMIC, in particular, the prevalence
and pattern of mental disorders among people attending
THPs commonly reflect the beliefs within communities
that people with severe mental illness are afflicted by
spirits or supernatural forces for which the effective
intervention is not orthodox medicine but traditional
health approaches [16, 17]. Consequently, both in view
of their significant presence within the health care sys-
tems in LMIC and the apparent preference for their care
by many in the community, suggestions have been made
for a more formal incorporation of the service of CAPs
into the health system [18, 19].
Three approaches have been suggested for a more formal
engagement of CAPs within the health system [11, 20]: (1)
evaluation of the efficacy of traditional healing practices; (2)
integration of traditional medicine into the national health
system and (3) providing training for traditional healers to
deliver safe and effective treatment. In view of their
abundance and closeness to the community [21], there is
little doubt that in most LMIC a process of collaboration
with CAPs is likely to be of importance in any attempt to
scale up mental health service. However, in sub-Saharan
Africa, one important challenge to a formal integration of
CAPs into the public mental health services is the frequent
observation that CAPs sometimes use harmful practices,
and abuses of human rights have been documented [22,
23]. These harmful practices include shackling of patients,
beating them, and making ritual scarification, a procedure
that carries a high risk of infection, including that of human
immunodeficiency virus (HIV). These practices commonly
reflect erroneous beliefs, which are common among both
healers and the public, about the underlying causation of
mental health problems and the effective interventions for
them [16].
There is evidence that, with the appropriate approach,
a collaborative care program can be developed between
THPs and the conventional public health sector [24]. Ex-
perience, especially in the area of HIV treatment, has
shown that while biomedical health practitioners may
initially have reservations about collaboration [25–27], a
program aimed at building mutual understanding and
respect can lead to beneficial collaborations [56]. King
pointed out that a key element for successful collabor-
ation is building of mutual respect between THPs and
biomedical health professionals through dialogue, ex-
change of information and readiness to learn from one
another [24]. However, no empirical evidence has yet
been provided about the possible boundaries of such
collaboration in the care of persons with severe mental
disorders, its feasibility, and its likely impact on patient
outcome. The present study, COllaborative Shared care
to IMprove Psychosis Outcome (COSIMPO) is designed
to provide such evidence.
Objectives
The main objective of COSIMPO is to compare the ef-
fectiveness of a collaborative, shared-care intervention
program implemented by CAPs and primary health care
providers (PHCPs) with care as usual in improving the
outcome of patients with psychosis.
Primary hypothesis
Patients presenting to CAP facilities engaged in collab-
orative shared care (CSC) with PHCPs will have better
outcome of psychosis compared to patients in enhanced
usual care at 6 months following entry into the trial as
measured by a significant mean reduction in symptoms
as rated by the Positive and Negative Syndrome scale
(PANSS) [28]. For the purpose of this study, a 7.5-point
difference on the PANSS total outcome scores between
the two groups will be regarded as a clinically meaning-
ful difference.
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Secondary hypotheses
Using outcome data collected at 3 and 6 months following
trial entry, we will test the following secondary hypotheses:
1. Persons with psychotic experience treated by CAPs
in the collaborative care program will be less likely
to receive harmful treatment or be subject to human
rights abuses (such as chaining, beating, starving,
exposure to natural elements, scarification, isolation,
fasting) than those in the care as usual
2. Participants in the intervention arm will be less
likely to experience victimization and abuse from
their caregivers. Victimization is defined as an act or
action that exploits or treats a patient unfairly
3. Participants in the intervention arm will have
significantly less disability in the areas of
psychological, occupational and social functioning as
measured with the World Health Organization’s
Disability Assessment Scale (WHO-DAS) than those
in the control arm
Method/design
The study is a single-blind, cluster randomized con-
trolled trial (RCT) being conducted in Nigeria and
Ghana. The sampling frame consists of all the clus-
ters in the 11 local government areas (LGAs) in and
around the city of Ibadan in Nigeria and Ashanti re-
gion in Ghana. A cluster is composed of a primary
health care clinic (PHC) and all the CAP facilities in
its neighborhood, defined as the catchment area typ-
ically served by the PHC. That is, a cluster has one
PHC and its neighboring CAP facilities, the number
of the latter being determined by distance, ease of
contact, and administrative considerations. Clusters
were composed such that the CAP facilities are read-
ily accessible to the PHCW in order to facilitate clin-
ical engagement and support. All CAP facilities in the
two study sites, previously identified and mapped dur-
ing the formative stage of the project, were allocated
to clusters. A total of 51 clusters were composed.
Randomization of clusters was carried out before re-
cruitment of trial participants (TPs). Allocation of
clusters to each of the study arms was conducted by
a statistician at the University of Ibadan (UI) Depart-
ment of Epidemiology and Statistics with no other in-
volvement in the day-to-day implementation of the
study. Allocation to the two arms was balanced by
site (Ghana versus Nigeria) and by size of the cluster,
using the number of beds in each cluster (small ver-
sus large). Patients who are invited will not be in-
formed of their allocation until their eligibility has
been established and they have consented to partici-
pate. Fifty-one clusters were randomized into the two
arms of the study across the two study sites.
Study settings
Nigeria
Ibadan in Nigeria is one of the largest cities in Africa.
The inhabitants are mostly of the Yoruba ethnic group.
Islam and Christianity are the predominant religions,
with about equal proportion of adherents, but traditional
religious worshipping is also common. There are 11
LGAs in and around the city of Ibadan (five urban, six
semi-urban or rural) with a current estimated total
population of 3,160,200. Each of the LGAs has between
10 and 18 PHCs. All 11 LGAs are included in the study.
Specialist mental health services are provided in the de-
partment of psychiatry of a teaching hospital, a psychiatric
unit of a general hospital, and one private hospital, by a
combined total of 12 psychiatrists. These orthodox facilities
have a total of about 120 psychiatric beds. There are about
71 facilities run by complementary alternative health pro-
viders, made up of traditional and faith healers, and provid-
ing mental health care. These facilities have an estimated
total of about 430 admission spaces at the time of the study.
Ghana
The Ashanti Region is located in south Ghana. It is the
third largest of 10 administrative regions in the country
but the most populous, with an estimated 2010 population
of 4,780,380, accounting for 19.1% of the country’s popu-
lation. Specialist mental health services are provided by
two psychiatrists working in a department of psychiatry of
a general hospital with 39 admission beds. The region has
more than 120 CAPs providing mental health care in facil-
ities with a total of 430 admission spaces. Seven districts
were selected for the study in Ashanti on the basis of hav-
ing the size of population required for the study and being
accessible to the research center.
Inclusion criteria
Potential trial participants (TPs) must be:
1. Aged 18 year or over and speak the study language
of Yoruba (Nigeria) or Twi (Ghana)
2. An inpatient at participating CAP facilities in the
selected clusters with a confirmed diagnosis of non-
organic psychosis as assessed by research interviewers
using the Structured Clinical Interview for Diagnostic
and Statistical Manual version IV (SCID) [29]
3. Symptomatic at the time of recruitment as indicated
by a minimum score of 60 on the total Positive and
Negative Symptoms Scale (PANSS) scale [28]
Exclusion criteria
1. Patients with serious physical illness and in need of
urgent medical attention (e.g., serious infection,
injury, etc.) as determined by the research assistants
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(RAs), a PHCP or by the independent social worker
during the process of assessing for capacity to
consent. This may be evident from the presence of
high-grade fever (temperature of 40 °C or greater),
apparent injury, state of consciousness or evidence
of profound confusion
2. Serious cognitive impairment that may interfere
with research assessment, such as having a prior
history of intellectual or learning disability as
assessed clinically by an independent social worker
3. Persons who would not be in the study area for at
least 6 months following recruitment, such as
patients brought in from other parts of the country
outside the study area who may return to their usual
domicile far from the study area after the period of
treatment. This information is obtained from
caregivers by the RAs
4. Women who are pregnant or attempting to become
pregnant during the study period. Pregnancy testing
will be conducted on all eligible female potential trial
patients by a research staff that has been
appropriately trained. Research assistants will seek
the assistance of the CAP to obtain a urine sample
from the potential female TP. Once a sample is
obtained, the RA will use a pregnancy test strip to
test for pregnancy. Only those whose test results
suggest that they are not pregnant will be enrolled
into the trial. Eligible female participants who
decline to have pregnancy test will be excluded.
Pregnant women are excluded because special
considerations and precautions might be required in
the decision to prescribe antipsychotic medications
for them that would fall outside the procedures
within the collaborative shared care. Such
considerations might require the expertise and
determination of a physician. Physicians are not
involved in the routine care of patients recruited to
COSIMPO except through referral from PHCPs
Informed consent procedure
Participants are recruited into the study either following
contact of the research team by the treating CAP or dur-
ing regular routine visits to the CAP facilities by the
RAs. All consecutively admitted patients considered by
the participating CAPs to have psychotic disorders at
the time of recruitment are approached for possible in-
clusion in the trial. Two levels of consent are sought
from patients: consent to be screened for eligibility, and,
if eligible, consent to participate in the trial (see section
on “Declaration” below).
Schedule of trial recruitment and participation
Enrollment into the study commenced on 19 September
2016 and is projected to end 30 June 2017. The last 6-
month follow-up assessment is expected to occur in De-
cember 2017. The schedule of enrollment and assessments
is as in the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Figure (Fig. 1).
Training of providers (see Table 1)
Participating providers in both arms of the study re-
ceived structured and targeted training prior to trial
commencement. Training was conducted separately for
CAPs and PHCPs. This separation was necessary to en-
sure the use of appropriate presentational approaches,
including language and content of training, which was
designed to be appropriate for the level of education and
literacy of these two distinct groups of providers. For ex-
ample, the training of the PHCPs, and not that of the
CAPs, included the use of the WHO Mental Health Gap
Action Program Intervention Guide (mhGAP-IG) [30] in
the management of psychosis. The local language of the
participating sites was used during the training of the
CAPs at each of the sites. Role-plays on specific compo-
nents and contents of the collaborative care were mod-
elled at these sessions. An important component of the
training of the PHCPs in the CSC arm was on dialogue
and engagement with CAPs. While formal and written
pre- and post-training tests were conducted for the
PHCPs, the CAPs were assessed verbally by asking par-
ticipants to describe individually the components of the
collaborations as well as steps to take when presented
with different clinical scenarios. The training of the
PHCPs was based on specific defining features of the
collaboration as well as on recognition and treatment of
psychosis, including the identification and response to
adverse events and medication side effects. Treatment
approaches for psychosis followed the mhGAP-IG speci-
fications, adapted, where necessary, for the context of
their use in a CAP facility. Training of both groups in-
cluded an understanding of the range of possibly harm-
ful and abusive practices and how to avoid them.
Interventions in COSIMPO
Intervention arm
The collaboration between the CAPs and the PHPCs taps
into the skills of both types of providers for the manage-
ment of patients with psychosis. The patients who are
treated within this collaborative program have access to
both orthodox medical care as well as complementary alter-
native medical approaches. However, it is important to note
that, in the design of COSIMPO, patients belong to the
CAPs primarily and the PHCP acts only in advisory and
supportive capacity in patient management. The role of the
PHCP is to help the CAP to provide safe and acceptable
care to patients, including promotion of, and respect for,
human rights and the avoidance of harmful practices. The
collaboration is based on mutual respect, trust, support,
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referral and advice between the CAPs and PHCPs. In the
collaborative arrangement, psychotropic medications are to
be prescribed only by trained orthodox health care
personnel, which is the PHCPs in the first instance or phy-
sicians or specialists if referrals are made to them by the
PHCP following consultation with the CAP. CAPs in the
intervention arm commit themselves to implementing en-
hanced patient care through the collaborative arrangement
with PHCPs.
In providing clinical support to the CAP, the PHCP en-
gages with the CAP, the patient, and the caregivers of the
patient. The PHCP conducts regular, weekly, scheduled
personal contacts with the CAPs as part of the collabor-
ation, using such contacts to reinforce information on best
clinical practice, provide information on patient rehabilita-
tion, and attend to other clinical issues that the CAPs may
bring to the attention of the PHCP. Beyond the regular
visits, the PHCP also responds to requests from the CAP
for urgent clinical needs as determined by the CAP. Such
needs may include acute deterioration of TPs’ mental sta-
tus, including instances of threats of violence or abscond-
ing, or emergent or worsening physical illness.
There are two main components of the collaborative
shared care:
1. Clinical support to respond to the medical need of
psychotic patients: this involves the provision of
medical care to patients, especially those in
conditions of acute psychotic disturbance, by the
PHCP following the request from CAP. This will
often entail the administration of psychotropic,
especially antipsychotic, medication
2. Clinical support to improve service on a continuous
basis: this involves engagement and interactions
Study Phases
Recruitment Baseline Follow-up
(months)
Events 3 6 12
Eligibility/inclusion criteria for providers X
Informed consent for Providers X
Randomization of clusters X
Training of Providers X
Eligibility/inclusion criteria for TPs and
caregivers
X
Capacity for consent by TPs X
Informed consent for TPs & caregiver X
Enrollment/Socio-demographic
questionnaires
X
SCID X
PANSS X x x x
WHODAS X x x x
Checklists on the experience of
harmful/abusive practices at CAPs facilities
and of victimization by caregivers
x x x
ISMI x x x x
FBIS x x x x
LCS x x x x
SUQ x x x x
Informed consent for process evaluation (PE) x
FGDs and Key Persons Interview for PE x
Fig. 1 Schedule of enrollment, intervention and assessments
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between PHCP and CAP during which the former
provides the latter with specific information to
improve service, organize rehabilitation for their
patients, and generally provide better care. This
interaction will involve the provision of specific
information by the PHCP to the CAP during
scheduled and regular weekly visits
All interactions and activities are documented fully
by the PHCP in each TP’s clinical records. These two
activities will form the basis of the evaluation of the
collaborative care both in regard its feasibility, the
fidelity of its implementation, as well as its impact or
effectiveness on patient outcome.
When a PHCP is involved in the care of a TP, the
PHCP assesses the patient at the CAP facility, provides
feedback to the CAP, and initiates treatment according
to treatment specifications for psychosis as described in
the mhGAP-IG. The PHCP continues to monitor the pa-
tient on at least weekly regular visits, but a more fre-
quent monitoring may be required, depending on the
clinical need of the patient (for example, administration
of specific medications may require daily or more visits
to monitor their effects). If the patient is taking herbal
medication, the PHCP takes this into consideration in
administering psychotropic medications. The PHCP may
refer a TP to see a physician or specialist, as necessary,
but always in consultation with the CAP.
Control arm
Providers in the control arm offer enhanced care as
usual (CAU). Usual care means that provides will oper-
ate as they currently do, without a structured approach
to collaboration between CAPs and PHCPs. However,
the care provided by the healers is enhanced through
interactive training workshops (see Table 1). For the
CAPs, the training consisted of (1) discussion about
their understanding of the concept of psychosis and the
information about the medical nature of psychosis, in-
cluding symptoms and course of illness; (2) a review of
the conventional and complimentary approaches to the
care of persons with psychosis; (3) identification of po-
tentially harmful treatment practices and possible ways
to avoid their use; and (4) basic concepts of human
rights. For the PHCPs, the training consisted of (1) a re-
view of the diagnosis of psychosis; (2) evidence-based
management of psychosis, using the mhGAP-IG; and (3)
the roles of the different levels of the mental health sys-
tem in the care of persons with psychosis. While the
training of the CAPs was over 2 days, that of the PHCPs
was over 1 day. The goal of the trainings was to improve
the care of persons with psychosis by both groups of
providers in the context of current practice in which for-
mal collaboration does not occur.
Responses to harmful treatment practices
COSIMPO is designed to engender collaboration be-
tween CAPs and PHCPs to enhance the outcome of pa-
tients with psychosis. CAPs, in the course of delivering
care to persons with severe mental health disorders, in-
cluding psychotic disorders, may use what can be
regarded as potentially harmful or abusive approaches.
These approaches are largely informed by their under-
standing of the nature of psychosis by CAPs and by the
need to curtail difficult clinical situations. For example,
CAPs might believe that patients who are aggressive are
Table 1 Schedule of training
Description of training
Primary care providers in the
intervention arm
3-day interactive training consisting of
(1) a review of the clinical features of
psychosis, including the assessment,
diagnosis and evidence-based manage-
ment of psychosis, using the mhGAP
Intervention Guide; (2) the roles of the
different levels of the mental health sys-
tem in the care of persons with psych-
osis; (3) the structure and components of
the collaborative shared care; and (4) ex-
pectations, roles, barriers and facilitators
for effective collaboration
Traditional and faith healers
in the intervention arm
2-day interactive training consisting of
(1) discussion about their understanding
of the concept of psychosis and
information about the medical nature of
psychosis, including symptoms and
course of illness; (2) a review of the
conventional and complimentary
approaches to the care of persons with
psychosis; (3) identification of potentially
harmful treatment practices and possible
ways to avoid their use; (4) basic
concepts of human rights; (5) the
structure and components of the
collaborative shared care; and (6)
expectations, roles, barriers and
facilitators for effective collaboration
Primary care providers in the
control arm
2-day interactive training consisting of
(1) a review of the clinical features of
psychosis, including the assessment,
diagnosis and evidence-based manage-
ment of psychosis, using the mhGAP
Intervention Guide and (2) the roles of
the different levels of the mental health
system in the care of persons with
psychosis
Traditional and faith healers
in the control arm
1-day interactive training consisting of
(1) discussion about their understanding
of the concept of psychosis and the
information about the medical nature of
psychosis, including symptoms and
course of illness; (2) a review of the
conventional and complimentary
approaches to the care of persons with
psychosis; (3) identification of potentially
harmful treatment practices and possible
ways to avoid their use; and (4) basic
concepts of human rights
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possessed of evil spirits and that physically beating such
patients might drive out the spirits. Also, in handling pa-
tients who are violent and at risk of harm to self or to
others, CAPs might feel the need to shackle such pa-
tients to restrict their movements and the attendant risk
of violence. All of these possible scenarios that might
lead to the use of harmful or abusive practices are ad-
dressed within COSIMPO through training of the pro-
viders, as described in this protocol, and through the
implementation of the collaboration with PHCPs who
are able to administer medications to calm agitated and
potentially violent patients.
There is need to reduce risks to all the TPs (in both
intervention and control arms) as much as possible while
getting the scientific and socially valuable information the
study has potential to offer. To this end, a schedule of re-
sponses to harmful practices is developed to guide the re-
search team to ensure that the team is not complicit to
the use of harmful practices by CAPs while at the same
time keeping the CAPs sufficiently engaged in the study in
order to answer the study questions. The schedule sets
out a typology of responses to some of the more common
forms of harmful practices that may occur in either arm
of the study. Responses are determined by the severity of
the practice (see Table 2). CAPs who engage in harmful
practices are expected to cooperate with the research team
in the execution of the responses to these practices and to
reduce such practices.
Disengagement of a CAP from the study will occur at
a defined instance of continued refusal to cooperate with
the study team in implementing these harm-reduction
responses. Given that harmful practices are often a part
of the standard of care of some CAPs and are among
what the project sets out to change, direct intervention
by the research team will be determined by the need to
ensure that the patient’s safety is promoted while ensur-
ing that the scientific objectives of the study are accom-
plished. The decision about when and how the research
team will take action or intervene with patients and/or
caregivers to ensure the protection of the patients
against the consequences of harmful practices is be
guided by specific rules. These rules are set out to en-
hance patient safety while giving sufficient scope for the
trial to meet its scientific objectives.
Thus, the PHCP will respond to harmful practices
in the intervention arm by providing appropriate
treatment to the patient and facilitating hospital refer-
ral when necessary. PHCPs will also directly intervene
with the patients and their caregivers by providing
advice on seeking alternative treatment in instances of
CAPs refusing to cooperate in the management of a
case of life threatening or “severe” harmful practice
or when such practice has been observed on more
than two occasions at a particular CAP facility. In the
control arm, where PHCPs are not involved, the trial
team will perform the role of engagement with pa-
tients and caregivers using the decision rules de-
scribed in Table 2.
Information on observed harmful practices will be
documented by the RAs and the PHCPs in a form de-
signed for the purpose to track the type of harmful prac-
tice, the rating of its severity, the immediate response of
the PHCP or RA to the observed practice, the outcome
and planned follow-up action.
Table 2 Schedule of response to harmful practices
Practice
observed
Thresholds of harm Responses control arm Responses intervention arm
Shackling 1. Short-term (hours)
2. Infections due to long-term
shackling
1. Continued monitoring
2. Study team works with CAP to
treat infections (by facilitating
access to medical care)
1. PHCP consultation and study team consultation to
employ alternative measures
2. PHCP will treat the infection; if more medical or
specialist care is required, PHCP will initiate referral to
such care
Beating 1. Evidence of beating – equipment
for beating present at site
2. Evidence of beating particular
patient (marks, scars)
1. Continued monitoring
2. Continued monitoring
1. PHCP consultation and study team consultation not to
beat patients
2. PHCP to reinforce the need to avoid practice
Scarification 1. Wounds have healed
2. Wounds are yet to heal
1. Continued monitoring
2. Study team works with CAP to
treat infections(by facilitating
referral to hospital)
1. PHCP to reinforce the need to avoid practice
2. PHCP will treat infection and reinforce the need to
avoid practice (and if necessary, initiate referral to medical
care)
Herbs 1. Patient shows non- serious signs of
side effects or drug reaction (e.g.,
vomiting, skin rash, etc.)
2. Patient is seriously unwell as a
reaction to herbs
1. Continued monitoring
2. Work with CAP to treat illness
(by facilitating referral to hospital)
1. PHCP monitors the situation and offers suggestions
about avoiding herbs
2. PHCP will assess and treat the condition; if more
medical or specialist care is required, PHCP and study
team will facilitate access to such care
Sexual
abuse
1. Any report or other evidence of
sexual abuse
1. Study team reports to legal
authorities
1. Study team reports to legal authorities
CAP complementary alternative health provider,PHCP primary health care provider
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Outcome evaluation
Outcome measures will be undertaken at 3 and 6 months
by RAs.
Primary outcome, to be assessed at 6 months, will be
the mean difference in recovery rate from psychosis as
measured by improvement or reduction in mean PANSS
total scores of patients in intervention arm (from base-
line) compared to those in the CAU arm. The PANSS is
chosen for its demonstrated acceptability and validity, its
proven sensitivity to change and our experience with its
use in our previous and on-going studies in Nigeria.
Secondary outcomes, to be assessed at 3 and 6 months,
include levels of disability, of self-stigma, the experience of
harmful treatment practices and of victimization by care-
giver as well as the course of the psychotic illness in four
key domains (symptoms, treatment, residence and work.
Assessment instruments
The psychosis section of the Structured Clinical Interview
for DSM-IV Axis 1 disorders (SCID) is used to confirm the
diagnosis of psychosis. The SCID is a semi-structured inter-
view for making the major DSM-IV Axis 1 diagnosis. Infor-
mation collected by trained RAs using the SCID is
reviewed by research psychiatrists to assign subtype diagno-
sis of psychosis and make a rating on course of the psych-
osis illness. The Positive and Negative Syndrome Scale
(PANSS) [28] is used to measure symptom severity of
psychosis at baseline, 3 and 6 months. Disability is being
measured with the World Health Organization’s Disability
Assessment Schedule 2.0, a generic tool for assessing health
and disability [31]. The Proxy version of WHO-DAS is
used when a TP is unable to provide reliable informa-
tion. The 29-item Internalized Stigma of Mental Illness
(ISMI) scale [32] is used to assess level of self-stigma.
The burden of caring for TPs by their caregivers is be-
ing assessed with the Family Burden Interview Schedule
(FBIS) [33], a standardized instrument designed for the.
The Life Chart Schedule (LCS) is being used to assess
the long-term course of the psychotic illness in four
key domains (symptoms, treatment, residence and
work) [34]. To capture the range of services and the cost
associate with their use, we use the Service Utilization
Questionnaire [35] (adapted for COSIMPO). The SUQ
systematically collects resource-use data, including cost of
care received from CAPs, consultations with PHCPs and
with other conventional health providers, use of herbs and
drugs, cost of treatment, including those of rituals and
sacrifices, and any other service use-related costs. Check-
lists of harmful treatment practices, human rights’ abuses
and of victimization, developed with information obtained
during the formative stages of the Partnership for Mental
Health Development in sub-Saharan Africa (PaM-D), are
used for the indicated purposes. These assessments are
conducted through both observation during visits by the
RAs to CAPs facilities and by patient interviews. For
example, respondents are asked if they have experienced
any of the practices or abuses in a defined period of time
(at the baseline, this will be in the previous 3 months, and
at follow-up assessments, this will be “since the last time
we spoke with you”). Every positive answer is followed by
exploration of the number of times that the event had
been experienced or the duration of its occurrence, which-
ever is relevant to the event.
In order to assess the extent to which collaboration af-
fects the knowledge and attitude of the CAPs, we ad-
minister the Knowledge About Schizophrenia Interview
(KASI) [36], a semi-structured interview that enquires
about respondent’s view about the diagnosis, symptom-
atology, etiology, course, prognosis and management of
schizophrenia, to the CAPs participating in the study at
the baseline and at the 6-month primary endpoint.
Discontinuation criteria
Trial participants will be discontinued from the trial at
any point in the following instances:
1. Development of a life-threatening physical illness in
which a referral to hospital is strongly advised
2. Serious suicidal intent (indicated by a suicidal plan
or attempt)
3. Becoming pregnant (confirmed by a detailed history
of menstruation and a urine test)
4. Incarceration
Patients, who during the routine weekly visit by the re-
search team or by the PHCP, are reported or observed to
meet any of these criteria, will be assessed immediately by
the trial manager on whose recommendation the site leader
will decide on possible discontinuation. The data collected
on any patient who discontinues from the study will be
retained in the study up to the time of the discontinuation
and included in the analysis on an intent-to-treat basis.
Blinding
TPs are not blinded to their treatment arms (as it is im-
possible to conceal the fact of collaboration or lack of it
from the patients). There are two groups of trained as-
sessors: the RAs who conduct the baseline and 3-month
assessments, and those conducting the 6-month primary
outcome evaluations. While the former cannot be blind
to patient trial arm (since they will conduct the baseline
assessment at the recruitment facility and the TP may
still be on admission at that facility for the 3-month out-
come assessment), the latter will be kept blind to trial al-
locations. TPs will be instructed not to disclose whether
or not they are receiving the intervention to the primary
outcome assessors. The primary outcome measure
(PANSS) will always be completed first in order to
Gureje et al. Trials  (2017) 18:462 Page 8 of 15
minimize the risk of bias in the event of unmasking dur-
ing the assessments and, if it occurs, the point of
unmasking will be recorded. Sensitivity analyses will be
carried out to assess the effect of unmasking on the pri-
mary outcomes.
Data collection and quality control
Data collection and capture are regulated by a series of
specific steps described in the Data Management Proto-
col. The protocol specifies steps to be taken to ensure
data integrity and quality.
Data is being collected using pen and paper. Collected
data is checked for accuracy and consistency by the RA,
the supervisor, the trial manager and the data-entry clerk
before it is entered using the Mobenzi software.
Mobenzi obeys series of programmed instructions such
as “Skip patterns” and thus ensures seamless data entry
and quality. At the end of every entered interview,
Mobenzi prompts a message pop-up to request the ac-
ceptance or rejection of the case.
Field work is monitored by research supervisors to
ensure that assessments are conducted according to
protocol specifications. Supervisors make random
checks on the quality of interviews (by physically ob-
serving at least 10% of all interviews conducted by an
RA) and randomly check the correct entry of study data
by RAs. The supervisors work under the direction of
the trial manager. The supervisors provide first-line re-
sponse to research and clinical issues as they arise in
the field and consult or refer difficult issues to the site
trial manager. Any unanticipated problem encountered
by an RA is reported to the supervisor who is required
to either solve the problem or report the problem to
the trial manager. Problems that cannot be solved by
the trial manager are referred to the site leader or the
principal investigator (PI).
The trial managers at both sites are responsible for the
coordination of the field work and are responsible to the
Trial Management Team through the site leader (in
Ghana) or the PI (in Ibadan). The trial manager at each
site ensures protocol adherence and monitors the work
of the RAs and research supervisors.
Data protection process
In order to ensure safety of data, collected data is en-
tered into password-protected computers by data-entry
clerks. Data will be backed up on another computer
(also password-protected and assessable only to the data
manager. Data captured in this way is, thereafter, trans-
ferred to the server/domain through the File Transfer
Protocol (FTP) synchronization process of Mobenzi. The
data manager at each site is responsible for uploading
field data via the Internet to an off-site server. The data
manager alone will have the access to the domain
through a user name and password for data protection
and security purpose.
All paper data files (quantitative and qualitative) are
being stored in lock-and-key cabinets and the computer-
ized data will be password-protected. Any back-ups
made of the computerized data are put on separate hard
drives which will also be password-protected. Only
named research staff have access to the data onsite.
Data monitoring
The trial is monitored by an independent Global
Data Monitoring and Safety Board (DSMB) consti-
tuted by the National Institute of Mental Health
(NIMH), the trial funders, as well as local, independ-
ent Institutional Review Boards (IRBs) at the UI and
the Kwame Nkrumah University of Science and
Technology, Kumasi.
The NIMH Global DSMB will ensure the safety of
TPs. The board, as well as the local IRBs at the study
sites, have reviewed and approved the study protocol, in-
formed consent and all relevant documents. The other
main responsibilities of the DSMB and the IRBs are, but
not limited to, the following:
□ Review of protocols, consent procedures, Consent
Forms and safety plans prior to the initiation of the
study
□ Monitoring of the progress of the study, including
recruitment and retention of participants, adverse
events, serious adverse events (SAEs) (which will be
reported as shown in Fig. 2), reasons for participant
withdrawal, adherence to the timeline of the study,
quality of data, and protocol violations
□ Make definitive and authoritative decisions about
the continuation, modification or termination of the
study based on the balance of adverse events and
beneficial outcomes. The data and safety monitoring
plan will involve the continuous evaluation of safety,
data quality and data timeliness. The PI will be
expected to continuously review data and patient
safety which will be reported at Trial Management
Committee (TMC) and Trial Steering Committee
(TSC) meetings and all discussions will be
documented. The PI will also submit twice yearly
progress report to the NIMH DSMB.
An independent professional trial monitoring
organization is engaged by the funders to conduct ran-
dom and scheduled auditing of the trial. The monitors
conducted site initiation to flag off patient recruitment
and have conducted three other visits to both study sites
at the time of this report. Site monitoring reports are
provided to the DSMB as well as to the study Institu-
tional Review Boards.
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Sample size and potential power of the trial
The primary outcome is symptom severity as assessed
with the PANSS score. Based on our previous naturalistic
follow-up study of patients with psychosis undergoing
treatment [37], we estimate that a mean difference of 7.5
units on the total PANSS outcome scores between the
two arms will represent a clinically significant difference
(given that a standard deviation of 20 was obtained for the
PANSS in that study). With the target effect size of 0.38,
an uninflated sample size of 112 patients per arm will be
required to provide a power of 80% and at an alpha of
0.05. We expect to be able to recruit an average total of
six patients per cluster. To take account of the cluster de-
sign, we inflate the estimated sample size by 1 + ((k − 1) ×
ICC)) where k is cluster size for analysis and ICC is the
intra-cluster correlation coefficient. We estimate an ICC
of 0.02 for the PANSS in primary care settings. Using the
resulting design effect of 1.10, the inflated sample size is
246.4 (224 × 1.10). With an estimated attrition of 20% at
6 months (an estimate supported by our experience with
the follow-up efforts so far) we will need to recruit a total
of 296 participants. A total of 49 clusters (rounded up to
50) will be required to reach the target number of partici-
pants. We have total of 51 clusters across the two study
sites and all are included in the trial.
Data analyses
Initial analyses will include comparisons of baseline char-
acteristics of individuals who consented and did not con-
sent, and participants who could and could not complete
baseline assessments, and of the distribution of potential
confounding factors. Findings will be reported as per Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines for cluster randomized controlled trials [38] in-
cluding a trial flow chart (see Fig. 3). This will include the
flow of clusters and participants through each stage of the
trial, including the number eligible, randomly assigned, re-
ceiving the intended treatment, completing the study
protocol and analyzed for the primary outcome.
The outcome measures will be summarized at base-
line, 3-month and 6-month follow-ups by intervention
arm and overall. These will be summarized by means
(SD), medians (IQR) or numbers and proportions as ap-
propriate (and including age, gender, baseline outcome
score), adjusting for cluster. For continuous outcomes,
histograms within each arm will be plotted in order to
assess how closely the scales follow a normal distribu-
tion to determine how to describe the outcomes and
how to properly do the inferential analysis. The clusters
will be described in terms of gender, education, country
site, and profile of the CAP.
Fig. 2 Reporting diagram of serious adverse events (SAEs)
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Outcome analyses
The primary analyses will be intention-to-treat at the 6-
month follow-up visit adjusted for baseline measures.
That is, after randomization, patients will be analyzed
according to their allocated treatment irrespective of the
treatment that they actually received. These analyses will
also disregard adherence to the intervention or with-
drawal from the trial. Random-effects logistic regression
will be used to analyze binary outcomes, adjusting for
country site and cluster size as random-effects variables.
Analyses of continuous outcomes will use random-
effects linear regression, additionally adjusting for the
baseline value of that outcome. Adjustments will also be
made for any a-priori-defined sets of potential
confounding variables for which randomization did not
achieve balance between the two arms at baseline. This
may include, for example, differences in the type of
CAPs (e.g., traditional healers versus faith healers). Effect
sizes will be reported as: (1) crude and adjusted relative
risks (ARRs) estimated using the marginal standardization
technique with 95% confidence intervals for the ratios es-
timated via the delta method [46] for binary outcomes
and (2) as mean differences and standardized mean
differences (SMDs), with 95% confidence intervals for
continuous outcomes. Missing data on the outcomes will
be estimated using multiple imputations in Stata. Second-
ary analyses will include repeated measures analyses of
data collected at 3 and 6 months, which make efficient
use of all available data. No interim analysis of outcomes
is planned.
Not meeting inclusion criteria (n=clusters)
Excluded (n=clusters)
Refused to participate)
Other reasons (clusters)
Excluded (n=patients)
Randomised (n=clusters)
Intervention : Collaborative care
. Treatment
.Patient in treatment at CAP facility
.PHCP responds to emergencies
. PHCP provides routine scheduled clinical support
. PHCP uses mhGAP-IG specifications for treatment of
psychosis
.PHCP and research staff monitor for trial patient for
harmful treatment practices
.PHCP engages with CAP, patient and caregiver and
is involved in patient’s discharge plan
Allocated to intervention group (Collaborative care)
(N= cluster)
Recruited patients (n=clusters)
Did not recruit patients (n=clusters)
Allocated to intervention group (Care as usual)
(N= cluster)
Recruited patients (n=clusters)
Did not recruit patients (n=clusters)
Excluded (n=patients)
Assessed for eligibilty and
invited to participate
(71 clusters)
Patient assessed for eligibility at
CAP facility (n=patients)
Patient assessed for eligibility at
CAP facility (n=patients)
Intervention : Care as usual
. Treatment
.Patient in treatment at CAP facility
.Research staff monitor trial patient for harmful
treatment practices
.CAP can refer to other treatment facilities
6-month follow-up assessments
3-month follow-up assessments
Lost to follow-up
(n=patients)
Analysed
(n=clusters)
(n=patients)
Analysed
(n=clusters)
(n=patients)
Lost to follow-up
(n=patients)
Fig. 3 COllaborative Shared care to IMprove Psychosis Outcome (COSIMPO) trial flow chart
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Economic measures
An economic evaluation is included in COSIMPO. For
this purpose, we will use the Service Utilization Question-
naire (SUQ), adapted for the purpose, to systematically
collect resource-use data, including any inpatient care,
consultations with health providers, use of drugs and la-
boratory tests, as well as payment in kind (such as chick-
ens and goats) and the offering of sacrifices and rituals For
this exercise, we will use previously computed estimates of
unit costs for resource inputs related to the use of public
facilities, including primary health care. We expect an in-
crease in the use of conventional services by the patients
in the intervention arm. On the other hand, patients in
the control arm may engage in more financially burden-
some visits to providers who offer less effective care. Since
psychosis and associated disability outcomes for the col-
laborative care intervention are expected to improve sig-
nificantly, the intervention will “dominate” usual care (i.e.,
better outcomes, less cost). Such a hypothesis negates the
need for a power calculation. If, however, costs turn out to
be higher in the intervention group, bootstrapped incre-
mental cost-effectiveness ratios for PANSS and WHO-
DAS disability scores level will be derived.
Dissemination and data-sharing policy
A publication policy has been designed and approved by
the investigators to guide authorship of publications.
Other than dissemination through academic channels
(journals and conferences), dissemination workshops are
planned for CAPs and PHCPs at the study sites at the
end of trial and analysis of results.
Our data-sharing procedure will be guided by the fol-
lowing principles: (1) the need to ensure that the data-
sets are first used to address the primary aims of the
project (which will be done within 2 years of data collec-
tion); (2) every effort will be made to offer unrestricted
access thereafter, with the only proviso being the contin-
ued protection of the anonymity of participants; and (3)
due acknowledgment is given by subsequent users to the
original source of the data of the funding. These condi-
tions are in line with the NIMH data-management and
data-sharing policy. We will work to ensure that the
data, whenever it becomes available to the public, is in
the form that can be understood and used by the re-
search community.
Discussion
There is a large treatment gap for people with psychosis
and other mental disorders that is far more evident in
LMIC where there is a dearth of mental health profes-
sionals [6, 39]. Bridging this treatment gap in the fore-
seeable future will involve the use of non-specialists
whose training takes fewer years than those of specialists
and who are, therefore, more likely to be available in
adequate numbers to bridge the existing treatment gap
in LMIC [40]. One common approach to utilizing these
available human resources is the use of task-shifting,
whereby primary health care workers are trained and su-
pervised to take on more roles in the care of persons
with mental health conditions [41]. This task-shifting or
task-sharing approach has been deployed to varying de-
grees of effectiveness in attempts to scale up services for
different conditions [41].
Other than inadequate numbers of specialists to meet
the need of persons in need of mental health service,
there is also the factor of cultural belief that determines
where patients with psychotic disorders and their care-
givers seek care [11]. Because of the shared understand-
ing of the nature of psychosis by the lay public and
providers of complementary health care, patients with
psychotic disorders are commonly drawn to the care of
traditional and faith healers who are also much more
easily accessible than mental health specialists. Given
this reality, a need to find a way of incorporating the ser-
vices of the healers into the mainstream public health
system has often been canvassed [18, 19]. However, in
order to do this, empirical evidence for the feasibility
and effectiveness of a formal engagement of the healers
with the public health system is required. Such evidence
will, among other goals, also assess to what extent is it
possible to improve the care provided by the healers es-
pecially in regard to a reduction in the use of harmful
and abusive treatment practices.
COSIMPO is designed as a test of the feasibility of
task-shifting for the care of persons with psychosis not
only to primary care providers, through training in the
delivery of evidence-based care for such persons, but
also through collaborative shared care for psychosis de-
livered by these providers and complementary health
providers. The study is designed to provide empirical
evidence for the effectiveness of this approach in
responding to the treatment gap for severe mental disor-
ders. The promise of the trial is not only in regard to
providing such evidence, but in also determining to what
extent a collaborative shared care between traditional
and faith healers, on the one hand, and primary health
care workers, on the other hand, can lead to a reduction
in the use of potentially harmful treatment practices by
the former. Addressing the concern about the use of
such practices in the treatment of severe mental disor-
ders will be an important contribution to the discussion
about the feasibility of integrating these healers into the
mainstream mental health services in LMIC.
The design of COSIMPO takes account of several im-
portant features that, from our formative studies, are
crucial in engendering trust and mutual respect. The
entry point to treatment for patients will be from the
traditional healers or faith healers (i.e., CAPs). The CAPs
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take responsibility for the patient and commence treat-
ment. The contract to care for the patient therefore lies
with the CAP. The discretion about when to seek clin-
ical support from or refer to the PHCP also lies with the
CAP. The PHCP in turn provides the necessary support
and assistance needed. In providing clinical support to
the CAP, the PHCP may engage with the CAP, the pa-
tient, and caregivers of the patient. Beyond specific refer-
rals and consultations, the PHCP will maintain regular
weekly scheduled personal contacts with the CAPs as
part of the collaboration, using such contacts to
reinforce information on best clinical practice, provide
information on patient rehabilitation, and attend to
other clinical issues that the CAPs may bring to the at-
tention of the PHCP.
The results of our formative work with CAPs showed
that their treatment modalities can be broadly grouped
into (1) harmful, (2) innocuous and (3) possibly helpful.
Harmful practices include shackling, beating/physical as-
saults, scarification, imposed long periods of fasting
(starvation) and isolation. PHCPs will discourage these
practices and offer to assist in managing patients who
are being exposed to such practices, possibly as a result
of the severity or challenging nature of their illness. Dur-
ing on-going engagement with the CAPs, PHCPs will al-
ways be mindful of the need for sensitivity, respect and
avoiding undermining the authority of the CAPs. In-
nocuous practices are not harmful to the patients and
very often reflect deep cultural and religious beliefs
shared by both patients/relatives and CAPs. Examples
include the use of sacrifices and rituals. PHCPs will be
trained and encouraged to remain open-minded about
the use of innocuous practices and to leave deeply held
belief systems undisturbed provided that they do not
have the potential to result in harm. Possibly helpful
practices within the CAM system include the use of
herbs, animal products and minerals. For the purpose of
potential referral/consultations to the PHCP, it is im-
portant that PHCPs are aware of the content and side ef-
fects of herbs, so as to be able to manage them if the
need arises. For this reason, CAPs who use herbs will be
encouraged to provide the names of the herbs. Research
team will seek to obtain the active ingredients of such
herbs from the literature. PHCPs will be provided with
this information as well as ways to respond to any ad-
verse events in the patients who are administered such
herbs and take appropriate action.
Cluster randomized controlled trials have peculiar
challenges. One of such challenges is that of possible
contamination. This was minimized in this study by
stratifying eligible and consenting clusters by LGA be-
fore allocation to the CSC or the CAU arm using a
computer-generated random number sequence, thus
avoiding contiguous clusters being in the same arm.
Furthermore, the availability of collaboration in the CSC
arm was not publicized to other CAPs. The stratification
of the clusters also took account of size, thus limiting
the potential limitation of differential recruitment into
the arms of the study. We have continued to monitor
the recruitment of participants into the arms. Subsample
selection bias has been avoided in this study by recruit-
ing all eligible and consenting participants from random-
ized clusters, thus maintaining the power of the study.
Trial status
The protocol version number is 14.0 submitted on the
7th December, 2016. Enrollment into the study com-
menced on 1st September, 2016 and projected to end
June 30, 2017.
Additional file
Additional file 1: Showing the SPIRIT Checklist for the COSIMPO trial.
(DOC 123 kb)
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